TherapeuticsMD (TXMD) Amortization of Deferred Charges (2011 - 2022)

TherapeuticsMD (TXMD) has reported Amortization of Deferred Charges for 8 consecutive years, with $2.6 million the latest figure, recorded in Q3 2022.

• For the quarter ending Q3 2022, Amortization of Deferred Charges rose 74.81% year-over-year to $2.6 million; the trailing twelve-month figure through Sep 2022 stood at $21.1 million (up 317.92% YoY), and the FY2021 full-year result was $5.7 million, up 124.68% from the prior year.
• Amortization of Deferred Charges retreated to $2.6 million in Q3 2022 per TXMD's latest filing, from $7.9 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $9.0 million in Q1 2022 and bottomed at $119753.0 in Q3 2018.
• Historically, Amortization of Deferred Charges has averaged $1.7 million across 5 years, with a median of $887000.0 in 2020.
• The sharpest annual moves came in 2021 and 2022: Amortization of Deferred Charges surged 54.98% in 2021, then jumped 611.32% in 2022.
• Over 5 years, Amortization of Deferred Charges stood at $119950.0 in 2018, then jumped by 127.74% to $273171.0 in 2019, then surged by 224.71% to $887000.0 in 2020, then soared by 72.6% to $1.5 million in 2021, then jumped by 68.65% to $2.6 million in 2022.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $2.6 million, $7.9 million, and $9.0 million for Q3 2022, Q2 2022, and Q1 2022 respectively.